Publicaciones en las que colabora con Catalina Requejo Rodríguez (16)

2020

  1. 6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata

    British Journal of Pharmacology, Vol. 177, Núm. 17, pp. 3957-3974

  2. Changes in Day/Night Activity in the 6-OHDA-Induced Experimental Model of Parkinson’s Disease: Exploring Prodromal Biomarkers

    Frontiers in Neuroscience, Vol. 14

2019

  1. Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and NRf2 regulation

    Neurobiology of Disease, Vol. 121, pp. 252-262

  2. Machine Learning Methods for Environmental-Enrichment-Related Variations in Behavioral Responses of Laboratory Rats

    Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)

  3. Machine learning methods for environmental-enrichment-related variations in behavioral responses of laboratory rats

    Understanding the Brain Function and Emotions: 8th International Work-Conference on the Interplay Between Natural and Artificial Computation, IWINAC 2019 Almería, Spain, June 3–7, 2019 Proceedings, Part I (Springer Suiza), pp. 420-427

  4. Nanodelivery of therapeutic agents in Parkinson's disease

    Progress in Brain Research (Elsevier B.V.), pp. 263-279

2018

  1. Correction to: Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson’s Disease (Molecular Neurobiology, (2018), 55, 1, (201-212), 10.1007/s12035-017-0733-x)

    Molecular Neurobiology

  2. Deleterious effects of VEGFR2 and RET inhibition in a preclinical model of Parkinson’s disease

    Molecular Neurobiology, Vol. 55, Núm. 1, pp. 201-212

  3. Nanodelivery of cerebrolysin and rearing in enriched environment induce neuroprotective effects in a preclinical rat model of Parkinson’s disease

    Molecular Neurobiology, Vol. 55, Núm. 1, pp. 286-299

2017

  1. Morphological Changes in a Severe Model of Parkinson’s Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors

    Molecular Neurobiology, Vol. 54, Núm. 10, pp. 7722-7735

  2. Nanoformulation: A Useful Therapeutic Strategy for Improving Neuroprotection and the Neurorestorative Potential in Experimental Models of Parkinson's Disease

    International Review of Neurobiology (Academic Press Inc.), pp. 99-122

2015

  1. Topographical Distribution of Morphological Changes in a Partial Model of Parkinson’s Disease—Effects of Nanoencapsulated Neurotrophic Factors Administration

    Molecular Neurobiology, Vol. 52, Núm. 2, pp. 846-858

2014

  1. Angioglioneurinas y enriquecimiento ambiental: una prometedora alianza para la restauración del cerebro

    Neuro-protección en enfermedades neuro y heredo-degenerativas (OmniaScience), pp. 209

  2. Angioglioneurins and environmental enrichment: A promising partnership for the restoration of the brain

    NEUROPROTECCION EN ENFERMEDADES NEURO Y HEREDO DEGENERATIVAS (OMNIASCIENCE), pp. 209-255

  3. Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease

    International Journal of Nanomedicine, Vol. 9, Núm. 1, pp. 2677-2687

2013

  1. In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 85, Núm. 3 PART B, pp. 1183-1190